An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated July 17, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on MK-677; the papers are listed at the end. Research summary, not a recommendation.
What it is
MK-677 (ibutamoren mesylate, also MK-0677) is a small synthetic molecule, not a peptide, developed by Merck in the 1990s. It is taken by mouth and copies the action of ghrelin, the stomach hormone that signals hunger and triggers growth hormone release, which is why it is called a growth hormone secretagogue. Merck tested it in several human trials, but it was never approved as a drug anywhere and is sold online as a research chemical.
How it works
MK-677 binds the ghrelin receptor (also called the growth hormone secretagogue receptor, GHSR-1a) in the pituitary gland and the hypothalamus, the brain region that controls hormones and hunger. This makes the pituitary release growth hormone in larger pulses, which in turn raises IGF-1 (insulin-like growth factor 1), the liver-made hormone that carries out many of growth hormone's effects on muscle, bone and fat. In older adults daily use raised growth hormone and IGF-1 into the range of healthy young adults. Because it acts on the hunger receptor it also increases appetite, and growth hormone's anti-insulin effect raised fasting blood sugar and lowered insulin sensitivity in trials.
What it has been studied for
Raising growth hormone and IGF-1 in healthy older adults (randomized trials)
Fat-free mass and body composition in older adults (one-year randomized trial)
Preventing protein loss during calorie restriction (randomized crossover study)
Recovery after hip fracture in older adults (phase IIb trial, stopped early for a safety signal)
Slowing Alzheimer's disease (randomized trial, no benefit)
Strength of the evidence
Human trialsSeveral randomized placebo-controlled trials by Merck and academic groups showed hormone and body-composition changes, but no trial showed gains in strength, function or disease outcomes and it was never approved.
What the literature reports on safety
In the trials the most common side effects were increased appetite, mild swelling of the lower legs and muscle pain, along with higher fasting blood sugar and reduced insulin sensitivity; a hip-fracture trial was stopped early because of a signal of congestive heart failure in a small number of patients, and a case of liver injury has been reported in a person using it on their own. It is not approved by the FDA or any regulator; in September 2023 the FDA placed ibutamoren mesylate on its compounding Category 2 list of bulk substances that raise significant safety risks, citing the potential for congestive heart failure. Growth hormone secretagogues are prohibited in sport by the World Anti-Doping Agency.
Review · Sinha DK, Balasubramanian A, et al. · Translational Andrology and Urology (2020) · PMID 32257855
Reviewed growth hormone secretagogues including ibutamoren, their effects on growth hormone, IGF-1 and body composition, and the gaps in long-term safety data.
Randomized trial · Nass R, Pezzoli SS, et al. · Annals of Internal Medicine (2008) · PMID 18981485
Over a year in healthy older adults, MK-677 raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass, but did not improve strength or function and raised fasting blood sugar.
Randomized trial · Chapman IM, Bach MA, et al. · Journal of Clinical Endocrinology and Metabolism (1996) · PMID 8954023
Within four weeks, once-daily MK-677 increased growth hormone pulses and brought IGF-1 into the young-adult range in older people, while fasting glucose rose.
Randomized trial · Adunsky A, Chandler J, et al. · Archives of Gerontology and Geriatrics (2011) · PMID 21067829
The trial was stopped early because of a congestive heart failure safety signal, and the authors judged the safety profile unfavorable in this older patient group.
Case series · Cobani E, Amin MS, et al. · BMJ Case Reports (2025) · PMID 40675653
Described liver inflammation in a person who had been taking MK-677 for two months.
Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), FDA 503A bulk drug substances category pages (September 2023 update and current page), written 2026-11-06.
The Longevity Stack (Fire Your Longevity Clinic) Unbreakable Podcast 198 (12×) · 2025-07-18read the hosted transcript
Preventing, Eliminating and Healing From Blood Clots - Unbreakable Podcast 214 (12×) · 2025-08-04read the hosted transcript
Ask the MK-677 Librarian
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about MK-677? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.